Drug
Dnl343
Dnl343: highest development phase Phase 2/3, developed by Denali Therapeutics. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Denali Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| DNL343 NCT05842941 | Phase 2/3 | Amyotrophic Lateral Sclerosis |
| DNL343 NCT05006352 | Phase 1 | Amyotrophic Lateral Sclerosis |
| DNL343 NCT04268784 | Phase 1 | Healthy Volunteers |
| DNL343 NCT04581772 | Phase 1 | Healthy Volunteers |
Latest
No recent events.
Follow Dnl343 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.